Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD). Click here to learn more.
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC. Click here to learn more.
GT0918-US-1002: Suzhou Kintor Pharmaceutical Inc.
The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer. Click here to learn more.